8-K current report · filed Nov 13, 2026

Inhibrx Biosciences, Inc. (INBX) 8-K Current Report: November 13, 2026

Item 2.02Item EX-99.1INBX overview

Short answer

Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Inhibrx announced financial results for the three and nine months ended September 30, 2026.

Inhibrx Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Inhibrx announced financial results for the three and nine months ended September 30, 2026
  • Full financial figures and management commentary are in Exhibit 99.1, the accompanying earnings release
  • Results may inform investors on operating performance, cash position, and development funding needs

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss $38.7M, or $2.46 per share, versus $35.3M, or $2.28, in Q3 2025
  • Cash $199.5M, while long-term debt rose to $276.7M from $100.6M at December 31, 2025
  • Pfizer license generated $2.0M revenue, providing limited non-dilutive funding relative to quarterly operating expenses
  • R&D expense fell to $26.0M, while G&A rose to $7.8M on ozekibart pre-commercialization spending
  • Key catalysts: ozekibart CTOS data November 19-20, 2026, and ordastobart HNSCC and NSCLC readouts expected mid-2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inhibrx Biosciences, Inc. 8-K filings

Get the next INBX 8-K as it lands

Follow INBX for push alerts, or ask the research agent what this filing means.